



Published in final edited form as:

Bioorg Med Chem. 2012 January 1; 20(1): 215–224. doi:10.1016/j.bmc.2011.11.008.

***N*-4-*t*-Butylbenzyl 2-(4-Methylsulfonylaminophenyl) Propanamide TRPV1 Antagonists : Structure Activity Relationships in the A-region**

Yongsoo Kim^a, Min-Jung Kil^a, Sang-Uk Kang^a, Hyun-Kyung Choi^a, HyungChul Ryu^a, Yeon-Sil Choi^a, Sook-Hyun Cho^a, Yongsung Cho^a, Rahul S. Bhondwe^a, Jin Hee Lee^b, Sun Choi^b, Larry V. Pearce^c, Vladimir A. Pavlyukovets^c, Matthew A. Morgan^c, Richard Tran^c, Jozsef Lazar^c, Peter M. Blumberg^c, and Jeewoo Lee^{a,*}

^aLaboratory of Medicinal Chemistry, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 151–742, Korea

^bCollege of Pharmacy, Division of Life & Pharmaceutical Sciences, and National Core Research Center for Cell Signaling & Drug Discovery Research, Ewha Womans University, Seoul 120-750, Korea

^cLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA

Abstract

Structure activity relationships for the A-region in a series of *N*-4-*t*-butylbenzyl 2-(4-methylsulfonylaminophenyl) propanamides as TRPV1 antagonists have been investigated. Among them, the 3-fluoro analogue **54** showed high binding affinity and potent antagonism for both rTRPV1 and hTRPV1 in CHO cells. Its stereospecific activity was demonstrated with marked selectivity for the (*S*)-configuration (**54S** versus **54R**). A docking study of **54S** with our hTRPV1 homology model highlighted crucial hydrogen bonds between the ligand and the receptor contributing to its potency.

Keywords

TRPV1 antagonists; analgesic; molecular modeling; capsaicin; resiniferatoxin

1. Introduction

The transient receptor potential V1 (TRPV1) receptor¹ is a molecular integrator of nociceptive stimuli, including protons,² heat,³ inflammatory mediators such as anandamide⁴ and lipoxygenase products,⁵ and vanilloids such as capsaicin (CAP)⁶ and resiniferatoxin (RTX)⁷. The receptor functions as a non-selective cation channel with high Ca²⁺ permeability and its activation leads to an increase in intracellular Ca²⁺ that results in excitation of primary sensory neurons and ultimately the central perception of pain.

TRPV1 antagonists are promising drug candidates. Therapeutic applications include inhibiting the transmission of nociceptive signaling from the periphery to the CNS as well as blocking other pathological states associated with this receptor. TRPV1 antagonists have thus emerged as novel and promising analgesic and antiinflammatory agents, particularly for

*To whom correspondence should be addressed. Phone: 82-2-880-7846, Fax: 82-2-888-0649, jeewoo@snu.ac.kr.

chronic pain and inflammatory hyperalgesia.⁸ The number of antagonists reported continues to increase and their clinical development has been extensively reviewed.^{9–13}

Previously, we have reported that a series of *N*-4-(methylsulfonylamino)benzyl thiourea analogues were effective antagonists of the action of capsaicin on rat TRPV1 (Figure 1).^{14–17} A prototype antagonist (**1**) showed high binding affinity and potent antagonism ($K_i = 63$ nM and $K_{i(\text{ant})} = 54$ nM in rTRPV1/CHO).¹⁴ We further found that 3-substituents of the 4-(methylsulfonylamino)phenyl group in the A-region affected the extent of agonism/antagonism. Thus, the 3-fluoro derivative **2** ($K_i = 53.5$ nM, $K_{i(\text{ant})} = 9.2$ nM for rTRPV1/CHO) was a potent antagonist not only of capsaicin stimulation of rTRPV1 but also of stimulation by temperature and pH.^{14,16} Conversely, the 3-methoxy derivative **3** showed a shift to partial agonism ($K_i = 51$ nM, 17% agonism and 84% antagonism for rTRPV1/CHO) while the binding affinity remained unaffected.¹⁵

In order to further optimize the antagonistic activities of *N*-4-(methylsulfonylamino)benzyl thioureas and avoid the potential toxicity associated with the thiourea functionality, we explored the amide B-region surrogates of the above parent thiourea antagonists in a series of simplified RTX derivatives and concluded that the propanamide B-region surrogates showed stereospecific high binding affinities and potent antagonism.¹⁸

As a continuation of our effort to optimize the 4-methylsulfonamide TRPV1 antagonists, we have investigated a series of 2-(4-methylsulfonylamino)phenyl propanamide analogues as TRPV1 antagonists. In this paper, we report the structure activity relationships of the A-region in a series of *N*-4-*t*-butylbenzyl 2-(4-methylsulfonylamino)phenyl propanamide TRPV1 antagonists. Further biological characterization and molecular modeling of a key antagonist from this series will also be described.

2. Chemistry

The syntheses of substituted *N*-(4-*tert*-butylbenzyl)-2-[4-(methylsulfonylamino)phenyl]propionamide derivatives are represented in Scheme 1.

Ethyl 2-(4-nitrophenyl)propionates (**5–16**) were prepared from the corresponding 2-halonitrobenzenes by the reaction of Makosza's vicarious nucleophilic substitution.¹⁹ The 4-nitro groups of **5–16** were reduced to amines **17–28** and then mesylated to give the corresponding 4-methylsulfonylamino compounds **29–40**, respectively. The esters of **29–40** were hydrolyzed to afford the acids **41–52** and then coupled with 4-*t*-butylbenzylamine to provide the final propionamides.

The *t*-butyl ester **62** was hydrolyzed to acid **63** under acidic conditions and was converted to methyl ester **64** and benzyl amide **65**, respectively. The 3-piperazinyl **69** was obtained from **68** by acidic hydrolysis. 3-Methyl **70** was synthesized from 3-bromo **56** using tetramethyltin with palladium catalyst. The compounds **53** and **71** were prepared from the corresponding acids previously reported¹⁸ by the coupling reaction.

The two enantiomers of **54**, **54S** and **54R**, were synthesized from the corresponding optically pure acids, prepared by the resolution method using L-phenylalanol,¹⁸ by the above coupling method.

3. Result and Discussion

3.1. Biological Activity

The binding affinities and potencies as agonists/antagonists of the synthesized TRPV1 ligands were assessed *in vitro* by a binding competition assay with [³H]RTX and by a

functional $^{45}\text{Ca}^{2+}$ uptake assay using rat and human TRPV1 heterologously expressed in Chinese hamster ovary (CHO) cells, as previously described.¹⁶ The results are summarized in Tables 1 and 2, together with the potencies of the previously reported thiourea antagonists **1–3**.^{14–16}

We started by preparing and characterizing two amide B-region surrogates of the parent thiourea **2**. Whereas acetamide **4** showed a reduction in binding affinity and antagonism by an order of magnitude, the propanamide (α -methyl acetamide) **54** exhibited higher affinity ($K_i = 46.2$ nM) and more potent antagonism ($K_{i(\text{ant})} = 7.6$ nM) compared to **2**. This result prompted us to investigate in detail the structure activity relationships of the A-region 4-methylsulfonylaminophenyl group in the series while the B- and C-regions were fixed as the propanamide and the 4-*t*-butylbenzyl group, respectively.

The unsubstituted analogue **53** showed a two-fold reduction in the binding affinity and antagonism compared to **54**, indicating that the fluoro atom is crucial for activity. The replacement of fluoro in **54** with bulkier halogens, such as chloro (**55**), bromo (**56**) and iodo (**57**), led to an increase in binding affinity, but with a 4-fold reduction in their potencies as antagonists. The 3,5-difluoro substituted analogue **58** exhibited a 2-fold enhancement in binding affinity and similar antagonism compared to **54**. On the other hand, the 2-halogen analogues, 2-fluoro (**59**) and 2-chloro (**60**), exhibited much reduced activities compared to the corresponding 3-halogen analogues **54** and **55**, probably due to a weaker electron-withdrawing effect toward the 4-sulfonamide in **59** and steric hinderance with the α -methyl in **60**.

As electron-withdrawing and hydrophilic groups, the cyano and carboxylate groups were introduced to the 3-position to provide **61–65**. Unfortunately, all of these compounds were found to be very weak or inactive antagonists.

As electron-donating groups, cyclic amines, methyl and methoxy groups were introduced to the 3-position. Whereas the 3-piperidinyl (**66**), morpholinyl (**67**), *N*-Boc piperazinyl (**68**) and piperazinyl analogues (**69**) showed marked loss of activity, the 3-methyl analogue (**70**) retained high potency in binding affinity and antagonism comparable with **54**. The 3-methoxy analogue (**71**) was intermediate, showing 10 to 30-fold reduced activity in binding affinity and antagonism.

The analysis of SAR indicated that electron withdrawing and lipophilic substituents at the 3-position appeared to be favorable for high binding and potent antagonism and the 3-fluoro substitution (**54**) was validated as the best for receptor antagonism.

For further exploration of the activity revealed by the racemate **54**, we prepared the two optically pure enantiomers of **54** and assessed their receptor binding and functional activities in rat and human (Table 2). Previously, our SAR investigation of the α -alkyl amide 6 B-region in a series of simplified RTX analogues had indicated that the stereocenter at the α -position was crucial for determining the potencies, binding affinities, and antagonism, with the *S*-configuration of the α -alkyl demonstrating high receptor potency.¹⁸ As anticipated, the receptor potencies revealed that the interaction of **54** was stereospecific. The (*S*)-isomer (**54S**) proved to be the active isomer with a $K_{i(\text{binding})} = 24.4$ nM and a $K_{i(\text{ant})} = 4.16$ nM for rTRPV1, values which were ca. two-fold more potent than the respective values for **54**. The activity of **54R**, in contrast, was 30- to 40-fold weaker.

The high potency of **54** was confirmed for human TRPV1. In hTRPV1, **54** showed similar potencies in binding affinity and antagonism compared to those in rTRPV1 with $K_i = 89$ nM, $K_{i(\text{CAP})} = 5.1$ nM and $K_{i(\text{pH})} = 12.7$ nM. The stereospecific activity of the active isomer

(**54S**) in binding affinity and functional antagonism was likewise observed with the hTRPV1, showing $K_i = 15.8$ nM, $K_{i(\text{CAP})} = 0.49$ nM and $K_{i(\text{pH})} = 8.3$ nM while **54R** again showed low potencies.

The further *in vivo* evaluation of **54** and **54S** will be presented elsewhere.

3.2. Molecular Modeling

We have built the tetramer homology model of rat TRPV1 (rTRPV1) and performed the docking studies of the representative TRPV1 ligands.²⁰ The rat and human TRPV1 have more than 85% sequence identity, and only five residues in the ligand binding site are different. Using the rTRPV1 model, the human TRPV1 (hTRPV1) model was constructed and refined by energy minimization.

As shown in Figure 2, the binding site of hTRPV1 has a deep bottom hole, surrounded by Tyr511 and Ser512, and an upper hydrophobic region with Leu547. The docking study showed that the sulfonylaminobenzyl group (A-region) of **54S** occupied the deep bottom hole. An oxygen atom of the sulfonamide group appeared to form a hydrogen bond with Ser512 and its –NH could make a hydrogen bond with Gly558. In addition, the carbonyl group in the B-region participated in hydrogen bonding with Tyr511. Moreover, the highly hydrophobic 4-*t*-butylbenzyl group (C-region) extended nicely toward the upper hydrophobic region of the binding site and made a hydrophobic interaction with Leu547.

It appeared that the *S*-stereochemistry of α -methyl in the B-region contributes to proper positioning of the B- and C-regions toward the upper region in the binding site. Consequently, **54S** fully occupied the binding site with these important interactions and it could explain the high potency of **54S**. This result is consistent with our previous structure-activity relationship (SAR) studies of the B-region in a series of simplified RTX analogues in which the (*S*)-propanamide proved to be the active isomer.¹⁸

4. Conclusion

The structure activity relationships of the A-region in a series of *N*-4-*t*-butylbenzyl 2-(4-methylsulfonylaminophenyl) propanamides as TRPV1 antagonists have been investigated. The analysis indicates that the 3-fluoro analogue **54** is validated as the best with high binding affinity and potent antagonism for both rTRPV1 and hTRPV1 in CHO cells. The two chiral isomers of **54** were synthesized and its (*S*)-configuration (**54S**) was found to be the active one, showing approximately a 2-fold enhancement in receptor activity compared to **54**, whereas the (*R*)-configuration showed marked loss of activity.

A docking study of **54S** with our hTRPV1 homology model indicates that the hydrophobic 4-*t*-butylbenzyl group (C-region) extended nicely toward the upper hydrophobic region of the binding site, making hydrophobic interactions with Leu547, while the 2-(3-fluoro-4-methylsulfonylaminophenyl) propanamide (A/B-regions) occupied the deep bottom hole, forming critical hydrogen bonds with Tyr511, Ser512 and Gly558 for high potency.

5. Experimental

5.1. Chemistry

5.1.1. General—All chemical reagents were commercially available. Melting points were determined on a melting point Buchi B-540 apparatus and are uncorrected. Silica gel column chromatography was performed on silica gel 60, 230–400 mesh, Merck. Proton NMR spectra were recorded on a JEOL JNM-LA 300 at 300 MHz and Bruker Analytik, DE/ AVANCE Digital 400 at 400 MHz. Chemical shifts are reported in ppm units with Me₄Si as

a reference standard. Mass spectra were recorded on a VG Trio-2 GC-MS. Combustion analyses were performed on an EA 1110 Automatic Elemental Analyzer, CE Instruments.

5.1.2. General Procedure for Alkylation—To a stirred solution of potassium *t*-butoxide (20 mmol) in DMF (20 mL) was added a mixture of nitrobenzene **4** (10 mmol) and ethyl 2-chloropropionate (10 mmol) at 0 °C dropwise. After being stirred for 10 min at 0 °C, the mixture was quenched with 1 N HCl solution, diluted with water and extracted with diethyl ether several times. The combined organic layers were washed with water and brine, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:10) as eluant.

5.1.2.1. Ethyl 2-(3-fluoro-4-nitrophenyl)propionate (5): 68% yield, yellow oil

¹H NMR (CDCl₃) δ 8.02 (dd, 1 H, *J* = 7.8, 8.0 Hz, H-5), 7.2–7.3 (m, 2 H, H-2,6), 4.14 (m, 2 H, CO₂CH₂CH₃), 3.78 (q, 1 H, *J* = 7.1 Hz, CHCH₃), 1.52 (d, 3 H, *J* = 7.1 Hz, CHCH₃), 1.22 (t, 3 H, *J* = 7.08 Hz, CO₂CH₂CH₃)

5.1.2.2. Ethyl 2-(3-chloro-4-nitrophenyl)propionate (6): 64% yield, yellow oil

¹H NMR (CDCl₃) δ 7.87 (d, 1 H, *J* = 8.4 Hz, H-5), 7.51 (d, 1 H, *J* = 1.8 Hz, H-2), 7.36 (dd, 1 H, *J* = 8.4, 1.8 Hz, H-6), 4.15 (m, 2 H, CO₂CH₂CH₃), 3.77 (q, 1 H, *J* = 7.2 Hz, CHCH₃), 1.53 (d, 3 H, *J* = 7.2 Hz, CHCH₃), 1.24 (t, 3 H, *J* = 7.08 Hz, CO₂CH₂CH₃)

5.1.2.3. Ethyl 2-(3-bromo-4-nitrophenyl)propionate (7): 52% yield, yellow oil

¹H NMR (CDCl₃) δ 7.83 (d, 1 H, *J* = 8.4 Hz, H-5), 7.69 (d, 1 H, *J* = 2 Hz, H-2), 7.40 (dd, 1 H, *J* = 8.4, 2 Hz, H-6), 4.15 (m, 2 H, CO₂CH₂CH₃), 3.75 (q, 1 H, *J* = 7.1 Hz, CHCH₃), 1.52 (d, 3 H, *J* = 7.1 Hz, CHCH₃), 1.24 (t, 3 H, *J* = 7.08 Hz, CO₂CH₂CH₃)

5.1.2.4. Ethyl 2-(3-iodo-4-nitrophenyl)propionate (8): 32% yield, yellow oil

¹H NMR (CDCl₃) δ 7.97 (d, 1 H, *J* = 2 Hz, H-2), 7.84 (d, 1 H, *J* = 8.4 Hz, H-5), 7.43 (dd, 1 H, *J* = 8.4, 2 Hz, H-6), 4.15 (m, 2 H, CO₂CH₂CH₃), 3.72 (q, 1 H, *J* = 7.1 Hz, CHCH₃), 1.52 (d, 3 H, *J* = 7.1 Hz, CHCH₃), 1.24 (t, 3 H, *J* = 7.08 Hz, CO₂CH₂CH₃)

5.1.2.5. Ethyl 2-(3,5-difluoro-4-nitrophenyl)propionate (9): 56% yield, yellow oil

¹H NMR (CDCl₃) δ 7.08 (bd, 2 H), 4.16 (m, 2 H, CO₂CH₂CH₃), 3.74 (q, 1 H, *J* = 7.1 Hz, CHCH₃), 1.53 (d, 3 H, *J* = 7.1 Hz, CHCH₃), 1.25 (t, 3 H, *J* = 7.1 Hz, CO₂CH₂CH₃)

5.1.2.6. Ethyl 2-(2-fluoro-4-nitrophenyl)propionate (10): 36% yield, yellow oil

¹H NMR (CDCl₃) δ 8.03 (dd, 1 H, *J* = 8.6, 2.2 Hz, H-3), 7.93 (dd, 1 H, *J* = 9.5, 2.2 Hz, H-5), 7.52 (t, 1 H, *J* = 8.3 Hz, H-6), 4.17 (q, 2 H, *J* = 7.1 Hz, CO₂CH₂CH₃), 4.08 (q, 1 H, *J* = 7.1 Hz, CHCH₃), 1.55 (d, 3 H, *J* = 7.1 Hz, CHCH₃), 1.23 (t, 3 H, *J* = 7.1 Hz, CO₂CH₂CH₃)

5.1.2.7. Ethyl 2-(2-chloro-4-nitrophenyl)propionate (11): 28% yield, yellow oil

¹H NMR (CDCl₃) δ 8.26 (d, 1 H, *J* = 2.4 Hz, H-3), 8.11 (dd, 1 H, *J* = 8.6, 2.4 Hz, H-5), 7.55 (d, 1 H, *J* = 8.6 Hz, H-6), 4.27 (q, 1 H, *J* = 7.1 Hz, CHCH₃), 4.18 (m, 2 H, CO₂CH₂CH₃), 1.55 (d, 3 H, *J* = 7.1 Hz, CHCH₃), 1.23 (t, 3 H, *J* = 7.1 Hz, CO₂CH₂CH₃)

5.1.2.8. Ethyl 2-(3-cyano-4-nitrophenyl)propionate (12): 20% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 8.31 (d, 1 H, $J = 8.4$ Hz, H-5), 7.87 (d, 1 H, $J = 2$ Hz, H-2), 7.77 (dd, 1 H, $J = 8.4, 2$ Hz, H-6), 4.17 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.88 (q, 1 H, $J = 7.2$ Hz, CHCH_3), 1.58 (d, 3 H, $J = 7.2$ Hz, CHCH_3), 1.25 (t, 3 H, $J = 7.2$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

IR (neat) 2236 (CN), 1731 (CO) cm^{-1}

5.1.2.9. Ethyl 2-(3-*t*-butoxycarbonyl-4-nitrophenyl)propionate (13): 44% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 7.79 (d, 1 H, $J = 8.3$ Hz, H-5), 7.58 (d, 1 H, $J = 1.8$ Hz, H-2), 7.49 (dd, 1 H, $J = 8.3, 1.8$ Hz, H-6), 4.11 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.78 (q, 1 H, $J = 7.2$ Hz, CHCH_3), 1.53 (s, 9 H, $\text{C}(\text{CH}_3)_3$), 1.50 (d, 3 H, $J = 7.2$ Hz, CHCH_3), 1.19 (t, 3 H, $J = 7.08$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.2.10. Ethyl 2-(3-piperidino-4-nitrophenyl)propionate (14): prepared from **5b** by the condensation with piperidine.

93% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 7.73 (d, 1 H, $J = 8.4$ Hz, H-5), 7.02 (d, 1 H, $J = 1.8$ Hz, H-2), 6.88 (dd, 1 H, $J = 8.4, 1.8$ Hz, H-6), 4.14 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.69 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.02 (m, 4 H, CH_2NCH_2), 1.65–1.75 (m, 4 H), 1.60 (m, 2 H), 1.49 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.23 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.2.11. Ethyl 2-(3-morpholino-4-nitrophenyl)propionate (15): prepared from **5b** by the condensation with morpholine.

58% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 7.77 (d, 1 H, $J = 8.4$ Hz, H-5), 7.05 (d, 1 H, $J = 1.8$ Hz, H-2), 7.00 (dd, 1 H, $J = 8.4, 1.8$ Hz, H-6), 4.14 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.85 (m, 4 H, CH_2OCH_2), 3.72 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.07 (m, 4 H, CH_2NCH_2), 1.51 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.23 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.2.12. Ethyl 2-(3-(*tert*-butoxycarbonyl)piperazino-4-nitrophenyl)propionate (16): prepared from **5b** by the condensation with *N*-(*tert*-butoxycarbonyl)piperazine.

48% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 7.77 (d, 1 H, $J = 8.4$ Hz, H-5), 7.06 (d, 1 H, $J = 1.8$ Hz, H-2), 7.00 (dd, 1 H, $J = 8.4, 1.8$ Hz, H-6), 4.14 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.72 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.12 (m, 8 H, $2 \times \text{CH}_2\text{NCH}_2$), 1.50 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.49 (s, 9 H, $\text{C}(\text{CH}_3)_3$), 1.23 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.3. General Procedure for Nitro Reduction

Method A: A suspension of nitro compound **5** (5 mmol) and 10% Pd-C (500 mg) in EtOH (30 mL) was hydrogenated under a balloon of hydrogen for 1 h and filtered through Celite. The filtrate was concentrated *in vacuo* and the residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:4) as eluant.

Method B: A suspension of nitro compound **5** (5 mmol) and activated iron (0.28 g, 5 mmol) in acetic acid (30 mL) was heated at 90 °C for 1 min. After being cooled at room temperature, the mixture was diluted with EtOH, filtered and the filtrate was concentrated *in*

vacuo. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:4) as eluant.

5.1.3.1. Ethyl 2-(4-amino-3-fluorophenyl)propionate (17): Method A, 94% yield, a colorless oil

$^1\text{H NMR}$ (CDCl_3) δ 6.96 (dd, 1 H, $J = 1.7, 11.9$ Hz, H-2), 6.87 (dd, 1 H, $J = 1.7, 8.3$ Hz, H-6), 6.71 (dd, 1 H, $J = 8.3, 11.9$ Hz, H-5), 4.11 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.58 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.45 (bs, 2 H, NH_2), 1.43 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.20 (t, 3 H, $J = 7.05$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.3.2. Ethyl 2-(4-amino-3-chlorophenyl)propionate (18): Method B, 88% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 7.20 (d, 1 H, $J = 2$ Hz, H-2), 7.00 (dd, 1 H, $J = 2, 8.1$ Hz, H-6), 6.71 (d, 1 H, $J = 8.1$ Hz, H-5), 4.11 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 4.00 (bs, 2 H, NH_2), 3.56 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 1.44 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.21 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.3.3. Ethyl 2-(4-amino-3-bromophenyl)propionate (19): Method B, 45% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 7.36 (d, 1 H, $J = 2$ Hz, H-2), 7.05 (dd, 1 H, $J = 2, 8.2$ Hz, H-6), 6.71 (d, 1 H, $J = 8.2$ Hz, H-5), 4.11 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 4.03 (bs, 2 H, NH_2), 3.56 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 1.43 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.21 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.3.4. Ethyl 2-(4-amino-3-iodophenyl)propionate (20): Method B, 34% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 7.57 (d, 1 H, $J = 2$ Hz, H-2), 7.08 (dd, 1 H, $J = 2, 8.3$ Hz, H-6), 6.69 (d, 1 H, $J = 8.3$ Hz, H-5), 4.12 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 4.05 (bs, 2 H, NH_2), 3.54 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 1.43 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.21 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.3.5. Ethyl 2-(4-amino-3,5-difluorophenyl)propionate (21): Method A, 99% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 6.79 (ddd, 2 H), 4.12 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.68 (bs, 2 H, NH_2), 3.56 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 1.43 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.22 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.3.6. Ethyl 2-(4-amino-2-fluorophenyl)propionate (22): Method A, 96% yield, colorless oil

$^1\text{H NMR}$ (CDCl_3) δ 7.04 (t, 1 H, $J = 8.3$ Hz, H-6), 6.41 (dd, 1 H, $J = 8.2, 2.2$ Hz, H-5), 6.35 (dd, 1 H, $J = 11.9, 2.2$ Hz, H-3), 4.12 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.87 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.64 (bs, 2 H, NH_2), 1.43 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.20 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.3.7. Ethyl 2-(4-amino-2-chlorophenyl)propionate (23): Method A, 97% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 7.08 (d, 1 H, $J = 8.4$ Hz, H-6), 6.69 (d, 1 H, $J = 2.4$ Hz, H-3), 6.55 (dd, 1 H, $J = 8.6, 2.4$ Hz, H-5), 4.13 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 4.07 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.69 (bs, 1 H, NH_2), 1.43 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.21 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.3.8. Ethyl 2-(4-amino-3-cyanophenyl)propionate (24): Method A, 42% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 7.25–7.35 (m, 2 H, H-2 & H-6), 6.70 (d, 1 H, $J = 8.4$ Hz, H-5), 4.36 (bs, 2 H, NH_2), 4.12 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.58 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 1.44 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.22 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.3.9. Ethyl 2-[4-amino-3-(*t*-butoxycarbonyl)phenyl]propionate (25): Method A, 89% yield, colorless oil

$^1\text{H NMR}$ (CDCl_3) δ 7.74 (d, 1 H, $J = 2.2$ Hz, H-2), 7.25 (dd, 1 H, $J = 2.2, 8.6$ Hz, H-6), 6.65 (d, 1 H, $J = 8.6$ Hz, H-5), 4.16 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 5.70 (bs, 2 H, NH_2), 3.63 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 1.62 (s, 9 H, $\text{C}(\text{CH}_3)_3$), 1.48 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.26 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.3.10. Ethyl 2-(4-amino-3-piperidinophenyl)propionate (26): Method A, 72% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 6.92 (d, 1 H, $J = 2$ Hz, H-2), 6.84 (dd, 1 H, $J = 2, 8.1$ Hz, H-6), 6.66 (d, 1 H, $J = 8.1$ Hz, H-5), 4.10 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.92 (bs, 2 H, NH_2), 3.58 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 2.83 (m, 4 H, CH_2NCH_2), 1.65–1.75 (m, 4 H), 1.57 (m, 2 H), 1.44 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.20 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.3.11. Ethyl 2-(4-amino-3-morpholinophenyl)propionate (27): Method A, 90% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 6.93 (d, 1 H, $J = 2$ Hz, H-2), 6.89 (dd, 1 H, $J = 2, 8.3$ Hz, H-6), 6.69 (d, 1 H, $J = 8.3$ Hz, H-5), 4.10 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.93 (bs, 2 H, NH_2), 3.84 (m, 4 H, CH_2OCH_2), 3.59 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 2.92 (m, 4 H, CH_2NCH_2), 1.45 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.21 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.3.12. Ethyl 2-[4-amino-3-*N*-(*tert*-butoxycarbonyl)piperazinophenyl]propionate (28): Method A, 94% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 6.90 (d, 1 H, $J = 2$ Hz, H-2), 6.88 (dd, 1 H, $J = 2, 8$ Hz, H-6), 6.69 (d, 1 H, $J = 8$ Hz, H-5), 4.10 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.93 (bs, 2 H, NH_2), 3.5–3.6 (m, 5 H, CHCH_3 and $\text{CH}_2\text{N}(\text{Boc})\text{CH}_2$), 2.86 (m, 4 H, CH_2NCH_2), 1.49 (s, 9 H, $\text{C}(\text{CH}_3)_3$), 1.44 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.21 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.4. General Procedure for Mesylation—A mixture of amine **6** (4 mmol) and methanesulfonyl chloride (6 mmol) in pyridine (10 mL) was stirred at 0 °C for 10 min. After aqueous workup, the residue was purified by flash column chromatography on silica gel using EtOAc:hexanes (1:2) as eluant.

5.1.4.1. Ethyl 2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionate (29): 91% yield, white solid mp = 81 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.50 (t, 1 H, $J = 8.3$ Hz, H-5), 7.0–7.1 (m, 2 H, H-2,6), 6.55 (bs, 1 H, NHSO_2), 4.12 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.68 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.02 (s, 3 H, SO_2CH_3), 1.48 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.22 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.4.2. Ethyl 2-[3-chloro-4-(methylsulfonylamino)phenyl]propionate (30): 90% yield, colorless oil

$^1\text{H NMR}$ (CDCl_3) δ 7.60 (d, 1 H, $J = 8.4$ Hz, H-5), 7.40 (d, 1 H, $J = 2$ Hz, H-2), 7.25 (dd, 1 H, $J = 8.4, 2$ Hz, H-6), 6.78 (bs, 1 H, NHSO_2), 4.14 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.67 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.02 (s, 3 H, SO_2CH_3), 1.49 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.23 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.4.3. Ethyl 2-[3-bromo-4-(methylsulfonylamino)phenyl]propionate (31): 96% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 7.60 (d, 1 H, $J = 8.4$ Hz, H-5), 7.55 (d, 1 H, $J = 2$ Hz, H-2), 7.28 (dd, 1 H, $J = 8.4, 2$ Hz, H-6), 6.76 (bs, 1 H, NHSO_2), 4.13 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.67 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.01 (s, 3 H, SO_2CH_3), 1.49 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.23 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.4.4. Ethyl 2-[3-iodo-4-(methylsulfonylamino)phenyl]propionate (32): 95% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 7.77 (d, 1 H, $J = 2$ Hz, H-2), 7.58 (d, 1 H, $J = 8.4$ Hz, H-5), 7.32 (dd, 1 H, $J = 8.4, 2$ Hz, H-6), 4.14 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.65 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.01 (s, 3 H, SO_2CH_3), 1.48 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.23 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.4.5. Ethyl 2-[3,5-difluoro-4-(methylsulfonylamino)phenyl]propionate (33): 95% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 7.05 (d, 2 H, $J = 8.4$ Hz), 4.14 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.71 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.47 (s, 3 H, SO_2CH_3), 1.50 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.25 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.4.6. Ethyl 2-[2-fluoro-4-(methylsulfonylamino)phenyl]propionate (34): 92% yield, colorless oil

$^1\text{H NMR}$ (CDCl_3) δ 7.27 (t, 1 H, $J = 8.1$ Hz, H-6), 7.02 (dd, 1 H, $J = 11, 2.2$ Hz, H-3), 6.94 (dd, 1 H, $J = 8.4, 2.2$ Hz, H-5), 4.16 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.96 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.04 (s, 3 H, SO_2CH_3), 1.49 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.23 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.4.7. Ethyl 2-[2-chloro-4-(methylsulfonylamino)phenyl]propionate (35): 89% yield, colorless oil

$^1\text{H NMR}$ (CDCl_3) δ 7.32 (d, 1 H, $J = 2.4$ Hz, H-3), 7.28 (d, 1 H, $J = 8.4$ Hz, H-6), 7.16 (dd, 1 H, $J = 8.6, 2.4$ Hz, H-5), 4.1–4.2 (m, 3 H, $\text{CO}_2\text{CH}_2\text{CH}_3$ and CHCH_3), 3.02 (s, 3 H, SO_2CH_3), 1.48 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.24 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.4.8. Ethyl 2-[3-cyano-4-(methylsulfonylamino)phenyl]propionate (36): 98% yield, yellow oil

$^1\text{H NMR}$ (CDCl_3) δ 7.55–7.7 (m, 3 H), 4.15 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.72 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.12 (s, 3 H, SO_2CH_3), 1.51 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.24 (t, 3 H, $J = 7.1$ Hz, $\text{CO}_2\text{CH}_2\text{CH}_3$)

5.1.4.9. Ethyl 2-[3-(*t*-butoxycarbonyl)-4-(methylsulfonylamino)phenyl]propionate (37): 99% yield, colorless oil

$^1\text{H NMR}$ (CDCl_3) δ 7.84 (d, 1 H, $J = 2.2$ Hz, H-2), 7.61 (d, 1 H, $J = 8.6$ Hz, H-5), 7.43 (dd, 1 H, $J = 8.6, 2.2$ Hz, H-6), 4.08 (m, 2 H, $\text{CO}_2\text{CH}_2\text{CH}_3$), 3.66 (q, 1 H, $J = 7.1$ Hz, CHCH_3),

3.00 (s, 3 H, SO₂CH₃), 1.56 (s, 9 H, C(CH₃)₃), 1.44 (d, 3 H, *J* = 7.1 Hz, CHCH₃), 1.19 (t, 3 H, *J* = 7.1 Hz, CO₂CH₂CH₃)

5.1.4.10. Ethyl 2-[3-piperidino-4-(methylsulfonylamino)phenyl]propionate (38): 96% yield, yellow oil

¹H NMR (CDCl₃) δ 7.79 (bs, 1 H, NHSO₂), 7.45 (d, 1 H, *J* = 8.4 Hz, H-5), 7.15 (d, 1 H, *J* = 2 Hz, H-2), 7.07 (dd, 1 H, *J* = 8.4, 2 Hz, H-6), 4.14 (m, 2 H, CO₂CH₂CH₃), 3.64 (q, 1 H, *J* = 7.1 Hz, CHCH₃), 3.04 (s, 3 H, SO₂CH₃), 2.77 (m, 4 H, CH₂NCH₂), 1.65–1.75 (m, 4 H), 1.59 (m, 2 H), 1.47 (d, 3 H, *J* = 7.1 Hz, CHCH₃), 1.22 (t, 3 H, *J* = 7.1 Hz, CO₂CH₂CH₃)

5.1.4.11. Ethyl 2-[3-morpholino-4-(methylsulfonylamino)phenyl]propionate (39): 92% yield, yellow oil

¹H NMR (CDCl₃) δ 7.72 (bs, 1 H, NHSO₂), 7.46 (d, 1 H, *J* = 8.4 Hz, H-5), 7.18 (d, 1 H, *J* = 2 Hz, H-2), 7.13 (dd, 1 H, *J* = 8.4, 2 Hz, H-6), 4.13 (m, 2 H, CO₂CH₂CH₃), 3.86 (m, 4 H, CH₂OCH₂), 3.66 (q, 1 H, *J* = 7.1 Hz, CHCH₃), 3.08 (s, 3 H, SO₂CH₃), 2.87 (m, 4 H, CH₂NCH₂), 1.48 (d, 3 H, *J* = 7.1 Hz, CHCH₃), 1.23 (t, 3 H, *J* = 7.1 Hz, CO₂CH₂CH₃)

5.1.4.12. Ethyl 2-[3-*N*-(*tert*-butoxycarbonyl)piperazino-4-(methylsulfonylamino)phenyl]propionate (40): 99% yield, yellow oil

¹H NMR (CDCl₃) δ 7.75 (bs, 1 H, NHSO₂), 7.45 (d, 1 H, *J* = 8.4 Hz, H-5), 7.15 (d, 1 H, *J* = 2 Hz, H-2), 7.13 (dd, 1 H, *J* = 8.4, 2 Hz, H-6), 4.13 (m, 2 H, CO₂CH₂CH₃), 3.66 (q, 1 H, *J* = 7.1 Hz, CHCH₃), 3.61 (m, 4 H, CH₂N(Boc)CH₂), 3.09 (s, 3 H, SO₂CH₃), 2.83 (m, 4 H, CH₂NCH₂), 1.49 (s, 9 H, C(CH₃)₃), 1.47 (d, 3 H, *J* = 7.1 Hz, CHCH₃), 1.22 (t, 3 H, *J* = 7.1 Hz, CO₂CH₂CH₃)

5.1.5. General Procedure for Hydrolysis—A solution of ester **7** (2 mmol) in H₂O and THF (1:2, 30 mL) was treated with lithium hydroxide (6 mmol) and stirred for 4 h at room temperature. The mixture was diluted with H₂O and CH₂Cl₂, acidified with 1 N HCl solution and extracted with CH₂Cl₂ several times. The combined organic layers were washed with water and brine, dried over MgSO₄ and concentrated *in vacuo*. The residue was crystallized by diethyl ether and n-hexane.

5.1.5.1. 2-[3-Fluoro-4-(methylsulfonylamino)phenyl]propionic acid (41): 97% yield, white solid, mp = 120 °C

¹H NMR (CDCl₃) δ 7.52 (t, 1 H, *J* = 8.04 Hz, H-5), 7.1–7.15 (m, 2 H, H-2,6), 6.60 (bs, 1 H, NHSO₂), 3.73 (q, 1 H, *J* = 7.1 Hz, CHCH₃), 3.03 (s, 3 H, SO₂CH₃), 1.51 (d, 3 H, *J* = 7.1 Hz, CHCH₃)

5.1.5.2. 2-[3-Chloro-4-(methylsulfonylamino)phenyl]propionic acid (42): 92% yield, pink solid, mp = 133–135 °C

¹H NMR (CDCl₃) δ 10.19 (bs, 1 H, CO₂H), 7.60 (d, 1 H, *J* = 8.4 Hz, H-5), 7.41 (d, 1 H, *J* = 1.8 Hz, H-2), 7.26 (dd, 1 H, *J* = 8.4, 1.8 Hz, H-6), 6.91 (bs, 1 H, NHSO₂), 3.72 (q, 1 H, *J* = 7.1 Hz, CHCH₃), 3.02 (s, 3 H, SO₂CH₃), 1.51 (d, 3 H, *J* = 7.1 Hz, CHCH₃)

5.1.5.3. 2-[3-Bromo-4-(methylsulfonylamino)phenyl]propionic acid (43): 99% yield, white solid, mp = 117–118 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.62 (d, 1 H, $J = 8.4$ Hz, H-5), 7.56 (d, 1 H, $J = 2$ Hz, H-2), 7.30 (dd, 1 H, $J = 8.4, 2$ Hz, H-6), 6.76 (bs, 1 H, NHSO_2), 3.72 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.02 (s, 3 H, SO_2CH_3), 1.52 (d, 3 H, $J = 7.1$ Hz, CHCH_3)

5.1.5.4. 2-[3-Iodo-4-(methylsulfonylamino)phenyl]propionic acid (44): 99% yield, white solid, mp = 102–103 °C

$^1\text{H NMR}$ (CD_3OD) δ 7.88 (d, 1 H, $J = 1.8$ Hz, H-2), 7.3–7.4 (m, 2 H, H-5 and H-6), 3.52 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 2.97 (s, 3 H, SO_2CH_3), 1.39 (d, 3 H, $J = 7.1$ Hz, CHCH_3)

5.1.5.5. 2-[3,5-Difluoro-4-(methylsulfonylamino)phenyl]propionic acid (45): 92% yield, white solid, mp = 78–79 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.00 (d, 2 H, $J = 8.4$ Hz), 6.03 (bs, 1 H, NHSO_2), 3.73 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.22 (s, 3 H, SO_2CH_3), 1.52 (d, 3 H, $J = 7.1$ Hz, CHCH_3)

5.1.5.6. 2-[2-Fluoro-4-(methylsulfonylamino)phenyl]propionic acid (46): 86% yield, pink solid, mp = 134–136 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.29 (t, 1 H, $J = 8.1$ Hz, H-6), 7.02 (dd, 1 H, $J = 11, 2.2$ Hz, H-3), 6.94 (dd, 1 H, $J = 8.4, 2.2$ Hz, H-5), 6.82 (bs, 1 H, NHSO_2), 4.02 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.05 (s, 3 H, SO_2CH_3), 1.52 (d, 3 H, $J = 7.1$ Hz, CHCH_3)

5.1.5.7. 2-[2-Chloro-4-(methylsulfonylamino)phenyl]propionic acid (47): 84% yield, pink solid, mp = 188–190 °C

$^1\text{H NMR}$ (CD_3OD) δ 7.24 (d, 1 H, $J = 8.4$ Hz, H-6), 7.21 (d, 1 H, $J = 2.4$ Hz, H-3), 7.07 (dd, 1 H, $J = 8.6, 2.4$ Hz, H-5), 4.02 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 2.88 (s, 3 H, SO_2CH_3), 1.35 (d, 3 H, $J = 7.1$ Hz, CHCH_3)

5.1.5.8. 2-[3-Cyano-4-(methylsulfonylamino)phenyl]propionic acid (48): 38% yield, white solid, mp = 108–111 °C

$^1\text{H NMR}$ (CD_3OD) δ 8.67 (d, 1 H, $J = 2.2$ Hz, H-2), 8.60 (dd, 1 H, $J = 8.4, 2.2$ Hz, H-6), 8.43 (d, 1 H, $J = 8.4$ Hz, H-5), 5.98 (bs, 2 H, NH_2), 4.64 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 4.05 (s, 3 H, SO_2CH_3), 2.18 (d, 3 H, $J = 7.1$ Hz, CHCH_3)

5.1.5.9. 2-[3-(*t*-Butoxycarbonyl)-4-(methylsulfonylamino)phenyl]propionic acid (49): 87% yield, yeollw solid, mp = 79–81 °C

$^1\text{H NMR}$ (CDCl_3) δ 10.53 (s, 1 H, CO_2H), 7.87 (d, 1 H, $J = 2.2$ Hz, H-2), 7.64 (d, 1 H, $J = 8.6$ Hz, H-5), 7.46 (dd, 1 H, $J = 8.6, 2.2$ Hz, H-6), 3.71 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.02 (s, 3 H, SO_2CH_3), 1.57 (s, 9 H, $\text{C}(\text{CH}_3)_3$), 1.48 (d, 3 H, $J = 7.1$ Hz, CHCH_3)

5.1.5.10. 2-[3-Piperidino-4-(methylsulfonylamino)phenyl]propionic acid (50): 83% yield, white solid, mp = 152 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.46 (d, 1 H, $J = 8.4$ Hz, H-5), 7.05–7.2 (m, 2 H, H-2 and H-6), 3.69 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.06 (s, 3 H, SO_2CH_3), 2.79 (m, 4 H, CH_2NCH_2), 1.68–1.8 (m, 4 H), 1.60 (m, 2 H), 1.50 (d, 3 H, $J = 7.1$ Hz, CHCH_3)

5.1.5.11. 2-[3-Morpholino-4-(methylsulfonylamino)phenyl]propionic acid (51): 93% yield, white solid, mp = 180 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.47 (d, 1 H, $J = 8.4$ Hz, H-5), 7.18 (d, 1 H, $J = 1.8$ Hz, H-2), 7.15 (dd, 1 H, $J = 8.4, 1.8$ Hz, H-6), 6.91 (bs, 1 H, NHSO_2), 3.86 (m, 4 H, CH_2OCH_2), 3.70 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.08 (s, 3 H, SO_2CH_3), 2.86 (m, 4 H, CH_2NCH_2), 1.51 (d, 3 H, $J = 7.1$ Hz, CHCH_3)

5.1.5.12. 2-[3-(*N*-*tert*-Butoxycarbonyl)piperazino-4-(methylsulfonylamino)phenyl]propionic acid (52): 93% yield, white solid, mp = 139–142 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.47 (d, 1 H, $J = 8.4$ Hz, H-5), 7.12–7.16 (m, 2 H, H-2 and H-6), 3.70 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.59 (m, 4 H, $\text{CH}_2\text{N}(\text{Boc})\text{CH}_2$), 3.08 (s, 3 H, SO_2CH_3), 2.80 (m, 4 H, CH_2NCH_2), 1.50 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.49 (s, 9 H, $\text{C}(\text{CH}_3)_3$)

5.1.6. General Procedure for Coupling—A mixture of acid **8** (10 mmol), 4-*t*-butylbenzylamine (12 mmol) and 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (12 mmol) in CH_2Cl_2 (20 mL) was stirred for 12 h at room temperature. The reaction mixture was filtered off and the filtrate was concentrated. The residue was purified by flash column chromatography on silica gel using EtOAc:hexanes as eluant.

5.1.6.1. *N*-(4-*tert*-Butylbenzyl)-2-[4-(methylsulfonylamino)phenyl]propionamide (53): prepared from the carboxylic acid previously reported by the general coupling procedure.

93% yield, white solid, mp = 77–79 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.32 (dt, 2 H), 7.27 (dt, 2 H), 7.18 (dt, 2 H), 7.11 (dt, 2 H), 6.96 (bs, 1 H, NHSO_2), 5.73 (bt, 1 H, NH), 4.38 (ddd, 2 H, ArCH_2NH), 3.55 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 2.98 (s, 3 H, SO_2CH_3), 1.52 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.29 (s, 9 H, $\text{C}(\text{CH}_3)_3$)

IR (KBr) 3277, 2963, 1649, 1512, 1464, 1333, 1228, 1153 cm^{-1}

MS (EI) m/z 388 (M^+)

5.1.6.2. *N*-(4-*tert*-Butylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (54): 78% yield, white solid, mp = 52–54 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.48 (t, 1 H, $J = 8.3$ Hz, H-5), 7.32 (bd, 2 H, Ar), 7.1–7.2 (m, 4 H, Ar), 6.73 (bs, 1 H, NHSO_2), 5.83 (bt, 1 H, NHCO), 4.36 (ddd of AB, 2 H, ArCH_2NH), 3.52 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.00 (s, 3 H, SO_2CH_3), 1.50 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.29 (s, 9 H, $\text{C}(\text{CH}_3)_3$)

IR (KBr) 3286, 2964, 1650, 1511, 1331, 1157, 1116 cm^{-1}

MS (FAB) m/z 407 (MH^+)

5.1.6.3. *N*-(4-*tert*-Butylbenzyl)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (55): 68% yield, white solid, mp = 126–129 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.60 (d, 1 H, $J = 8.2$ Hz, H-5), 7.43 (d, 1 H, $J = 2$ Hz, H-2), 7.34 (bd, 2 H, Ar), 7.24 (dd, 1 H, $J = 8.2, 2$ Hz, H-6), 7.14 (bd, 2 H, Ar), 6.75 (bs, 1 H, NHSO_2), 5.68 (bt, 1 H, NHCO), 4.38 (ddd of AB, 2 H, ArCH_2NH), 3.50 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.01 (s, 3 H, SO_2CH_3), 1.52 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.30 (s, 9 H, $\text{C}(\text{CH}_3)_3$)

IR (KBr) 3287, 2963, 1648, 1497, 1331, 1236, 1157 cm^{-1}

MS (FAB) m/z 423 (MH⁺)

5.1.6.4. *N*-(4-*tert*-Butylbenzyl)-2-[3-bromo-4-(methylsulfonylamino)phenyl]propionamide (56): 76% yield, white solid, mp = 66–67 °C

¹H NMR (CDCl₃) δ 7.55–7.6 (m, 2 H, H-2 and H-5), 7.33 (d, 2 H, J = 8.1 Hz, Ar), 7.27 (dd, 1 H, J = 1.8, 8.6 Hz, H-6), 7.12 (d, 2 H, J = 8.1 Hz, Ar), 6.80 (bs, 1 H, NHSO₂), 5.91 (bt, 1 H, NHCO), 4.36 (ddd of AB, 2 H, ArCH₂NH), 3.50 (q, 1 H, J = 7.1 Hz, CHCH₃), 2.98 (s, 3 H, SO₂CH₃), 1.50 (d, 3 H, J = 7.1 Hz, CHCH₃), 1.29 (s, 9 H, C(CH₃)₃)

IR (KBr) 3292, 2963, 1649, 1493, 1387, 1330, 1233, 1157, 1044 cm⁻¹

MS (FAB) m/z 467 (MH⁺)

5.1.6.5. *N*-(4-*tert*-Butylbenzyl)-2-[3-iodo-4-(methylsulfonylamino)phenyl]propionamide (57): 75% yield, white solid, mp = 71 °C

¹H NMR (CDCl₃) δ 7.80 (d, 1 H, J = 2 Hz, H-2), 7.59 (d, 1 H, J = 8.3 Hz, H-5), 7.3–7.37 (m, 3 H, Ar), 7.13 (d, 2 H, J = 8.1 Hz, Ar), 6.60 (bs, 1 H, NHSO₂), 5.67 (bt, 1 H, NHCO), 4.39 (ddd of AB, 2 H, ArCH₂NH), 3.48 (q, 1 H, J = 7.1 Hz, CHCH₃), 3.01 (s, 3 H, SO₂CH₃), 1.52 (d, 3 H, J = 7.1 Hz, CHCH₃), 1.30 (s, 9 H, C(CH₃)₃)

IR (KBr) 3299, 2963, 1649, 1539, 1486, 1385, 1329, 1231, 1115, 1036 cm⁻¹

MS (FAB) m/z 515 (MH⁺)

5.1.6.6. *N*-(4-*tert*-Butylbenzyl)-2-[3,5-difluoro-4-(methylsulfonylamino)phenyl]propionamide (58): 70% yield, white solid, mp = 80–81 °C

¹H NMR (CDCl₃) δ 7.35 (dt, 2 H), 7.15 (bd, 2 H, Ar), 6.99 (dt, 2 H, Ar), 6.16 (bs, 1 H, NHSO₂), 5.76 (bt, 1 H, NHCO), 4.38 (ddd of AB, 2 H, J = 5.7, 14.5, 33.7 Hz, ArCH₂NH), 4.12 (q, 1 H, J = 7.1 Hz, CHCH₃), 3.02 (s, 3 H, SO₂CH₃), 1.50 (d, 3 H, J = 7.1 Hz, CHCH₃), 1.30 (s, 9 H, C(CH₃)₃)

IR (KBr) 3376, 2962, 1653, 1511, 1454, 1331, 1231, 1155, 1023, 1155, 1023 cm⁻¹

MS (FAB) m/z 425 (MH⁺)

5.1.6.7. *N*-(4-*tert*-Butylbenzyl)-2-[2-fluoro-4-(methylsulfonylamino)phenyl]propionamide (59): 63% yield, white solid, mp = 111–113 °C

¹H NMR (CDCl₃) δ 7.3–7.38 (m, 3 H, H-6 and Ar), 7.28 (bs, 1 H, NHSO₂), 7.15 (bd, 2 H, Ar), 7.02 (dd, 1 H, J = 11.4, 2.2 Hz, H-3), 6.87 (dd, 1 H, J = 8.4, 2.2 Hz, H-5), 5.88 (bt, 1 H, NHCO), 4.41 (ddd of AB, 2 H, ArCH₂NH), 3.84 (q, 1 H, J = 7.1 Hz, CHCH₃), 3.00 (s, 3 H, SO₂CH₃), 1.52 (d, 3 H, J = 7.1 Hz, CHCH₃), 1.30 (s, 9 H, C(CH₃)₃)

IR (KBr) 3277, 2963, 1652, 1509, 1396, 1328, 1266, 1151, 1117 cm⁻¹

MS (FAB) m/z 407 (MH⁺)

5.1.6.8. *N*-(4-*tert*-Butylbenzyl)-2-[2-chloro-4-(methylsulfonylamino)phenyl]propionamide (60): 46% yield, white solid, mp = 134–136 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.44 (d, 1 H, $J = 8.4$ Hz, H-6), 7.34 (bd, 2 H, Ar), 7.29 (d, 1 H, $J = 2.2$ Hz, H-3), 7.15 (bd, 2 H, Ar), 7.07 (dd, 1 H, $J = 8.4, 2.2$ Hz, H-5), 5.88 (bt, 1 H, NHCO), 4.40 (ddd of AB, 2 H, ArCH_2NH), 3.84 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.00 (s, 3 H, SO_2CH_3), 1.52 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.30 (s, 9 H, $\text{C}(\text{CH}_3)_3$)

IR (KBr) 3286, 2963, 1650, 1608, 1494, 1376, 1324, 1154 cm^{-1}

MS (FAB) m/z 423 (MH^+)

5.1.6.9. *N*-(4-*tert*-Butylbenzyl)-2-[3-cyano-4-(methylsulfonylamino)phenyl]propionamide (61): 30% yield, white solid, mp = 102–105 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.67 (d, 1 H, $J = 8.4$ Hz, H-5), 7.63 (d, 1 H, $J = 1.8$ Hz, H-2), 7.58 (dd, 1 H, $J = 8.4, 1.8$ Hz, H-6), 7.35 (bd, 2 H, Ar), 7.15 (bd, 2 H, Ar), 5.73 (bt, 1 H, NHCO), 4.38 (ddd of AB, 2 H, ArCH_2NH), 3.51 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.11 (s, 3 H, SO_2CH_3), 1.53 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.31 (s, 9 H, $\text{C}(\text{CH}_3)_3$)

IR (KBr) 3285, 2963, 2231, 1649, 1501, 1404, 1334, 1157, 1114 cm^{-1}

MS (FAB) m/z 414 (MH^+)

5.1.6.10. *N*-(4-*tert*-Butylbenzyl)-2-[3-(*t*-butoxycarbonyl)-4-(methylsulfonylamino)phenyl]propionamide (62): 53% yield, white solid, mp = 75–77 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.90 (d, 1 H, $J = 2.2$ Hz, H-2), 7.67 (d, 1 H, $J = 8.6$ Hz, H-5), 7.50 (dd, 1 H, $J = 8.6, 2.2$ Hz, H-6), 7.33 (bd, 2 H, Ar), 7.13 (bd, 2 H, Ar), 5.74 (bt, 1 H, NHCO), 4.38 (ddd of AB, 2 H, ArCH_2NH), 3.55 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.04 (s, 3 H, SO_2CH_3), 1.60 (s, 9 H, $\text{CO}_2\text{C}(\text{CH}_3)_3$), 1.53 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.30 (s, 9 H, $\text{C}(\text{CH}_3)_3$)

IR (KBr) 2966, 1678, 1500, 1395, 1330, 1253, 1153, 1089 cm^{-1}

MS (FAB) m/z 489 (MH^+)

5.1.6.11. *N*-(4-*tert*-Butylbenzyl)-2-[3-carboxyl-4-(methylsulfonylamino)phenyl]propionamide (63): prepared from **62** by acid hydrolysis.

74% yield, white solid, mp = 180–183 °C

$^1\text{H NMR}$ (CD_3OD) δ 8.45 (bt, 1 H, NH), 8.12 (d, 1 H, $J = 2.2$ Hz, H-2), 7.64 (d, 1 H, $J = 8.6$ Hz, H-5), 7.56 (dd, 1 H, $J = 8.6, 2.2$ Hz, H-6), 7.30 (bd, 2 H, Ar), 7.11 (bd, 2 H, Ar), 4.29 (bs, 2 H, ArCH_2NH), 3.69 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.04 (s, 3 H, SO_2CH_3), 1.46 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.27 (s, 9 H, $\text{C}(\text{CH}_3)_3$)

IR (KBr) 3429, 2964, 1678, 1626, 1503, 1338, 1206, 1153 cm^{-1}

MS (EI) m/z 432 (M^+)

5.1.6.12. *N*-(4-*tert*-Butylbenzyl)-2-[3-(methoxycarbonyl)-4-(methylsulfonylamino)phenyl]propionamide (64): prepared from **63** by the diazomethane reaction.

79% yield, white solid, mp = 142–144 °C

$^1\text{H NMR}$ (CDCl_3) δ 10.38 (s, 1 H, NHSO_2), 8.03 (d, 1 H, $J = 2.2$ Hz, H-2), 7.70 (d, 1 H, $J = 8.6$ Hz, H-5), 7.51 (dd, 1 H, $J = 8.6, 2.2$ Hz, H-6), 7.33 (bd, 2 H, Ar), 7.13 (bd, 2 H, Ar), 5.69 (bt, 1 H, NHCO), 4.38 (ddd of AB, 2 H, ArCH_2NH), 3.94 (s, 3 H, CO_2CH_3), 3.53 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.05 (s, 3 H, SO_2CH_3), 1.54 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.30 (s, 9 H, $\text{C}(\text{CH}_3)_3$)

IR (KBr) 3296, 2961, 1688, 1608, 1503, 1398, 1332, 1258, 1156, 1088 cm^{-1}

MS (FAB) m/z 447 (MH^+)

5.1.6.13. *N*-(4-*tert*-Butylbenzyl)-2-[3-(benzylamino)carbonyl-4-(methylsulfonylamino)phenyl]propionamide (65): prepared from **63** by coupling with benzyl amine.

88% yield, white solid, mp = 79–81 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.65 (d, 1 H, $J = 8.6$ Hz, H-5), 7.61 (d, 1 H, $J = 2.2$ Hz, H-2), 7.3–7.38 (m, 8 H), 7.11 (bd, 2 H, Ar), 5.84 (bt, 1 H, NHCO), 4.60 (d, 2 H, $J = 5.88$ Hz, NHCH_2Ph), 4.35 (ddd of AB, 2 H, ArCH_2NH), 3.48 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 2.97 (s, 3 H, SO_2CH_3), 1.50 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.29 (s, 9 H, $\text{C}(\text{CH}_3)_3$)

IR (KBr) 3303, 2963, 1644, 1537, 1333, 1267, 1152 cm^{-1}

MS (FAB) m/z 522 (MH^+)

5.1.6.14. *N*-(4-*tert*-Butylbenzyl)-2-[3-piperidino-4-(methylsulfonylamino)phenyl]propionamide (66): 86% yield, white solid, mp = 125 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.78 (bs, 1 H, NHSO_2), 7.45 (d, 1 H, $J = 8.4$ Hz, H-5), 7.31 (bd, 2 H, Ar), 7.15 (d, 1 H, $J = 2$ Hz, H-2), 7.10 (bd, 2 H, Ar), 7.05 (m, 1 H, $J = 8.4, 2$ Hz, H-6), 5.59 (bt, 1 H, NHCO), 4.38 (d of AB, 2 H, $J = 5.7$ Hz, ArCH_2NH), 3.52 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.04 (s, 3 H, SO_2CH_3), 2.75 (m, 4 H, CH_2NCH_2), 1.65–1.75 (m, 4 H), 1.6 (m, 2 H), 1.52 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.29 (s, 9 H, $\text{C}(\text{CH}_3)_3$)

IR (KBr) 3290, 2937, 1648, 1501, 1335, 1242, 1157 cm^{-1}

MS (FAB) m/z 472 (MH^+)

5.1.6.15. *N*-(4-*tert*-Butylbenzyl)-2-[3-morpholino-4-(methylsulfonylamino)phenyl]propionamide (67): 84% yield, white solid, mp = 78 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.69 (bs, 1 H, NHSO_2), 7.46 (d, 1 H, $J = 8.2$ Hz, H-5), 7.32 (bd, 2 H, Ar), 7.18 (d, 1 H, $J = 1.8$ Hz, H-2), 7.08–7.15 (m, 3 H, H-6 and Ar), 5.63 (bt, 1 H, NHCO), 4.38 (d of AB, 2 H, $J = 5.5$ Hz, ArCH_2NH), 3.85 (m, 4 H, CH_2OCH_2), 3.52 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.08 (s, 3 H, SO_2CH_3), 2.84 (m, 4 H, CH_2NCH_2), 1.52 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.29 (s, 9 H, $\text{C}(\text{CH}_3)_3$)

IR (KBr) 3293, 2962, 1650, 1505, 1455, 1333, 1156, 1115 cm^{-1}

MS (FAB) m/z 474 (MH^+)

5.1.6.16. *N*-(4-*tert*-Butylbenzyl)-2-[3-(*N*-*tert*-butoxycarbonyl)piperazino-4-(methylsulfonylamino)phenyl]propionamide (68): 88% yield, white solid, mp = 103 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.66 (bs, 1 H, NHSO_2), 7.46 (d, 1 H, $J = 8.2$ Hz, H-5), 7.32 (bd, 2 H, Ar), 7.15 (d, 1 H, $J = 1.8$ Hz, H-2), 7.08–7.13 (m, 3 H, H-6 and Ar), 5.60 (bt, 1 H, NHCO), 4.38 (ddd of AB, 2 H, ArCH_2NH), 3.58 (m, 4 H, $\text{CH}_2\text{N}(\text{Boc})\text{CH}_2$), 3.49 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.08 (s, 3 H, SO_2CH_3), 2.79 (m, 4 H, CH_2NCH_2), 1.55 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.49 (s, 9 H, $\text{C}(\text{CH}_3)_3$), 1.30 (s, 9 H, $\text{C}(\text{CH}_3)_3$)

IR (KBr) 3294, 2965, 1690, 1502, 1366, 1333, 1245, 1160 cm^{-1}

MS (FAB) m/z 573 (MH^+)

5.1.6.17. *N*-(4-*tert*-Butylbenzyl)-2-[3-piperazino-4-(methylsulfonylamino)phenyl]propionamide (69): prepared from **9o** by acid hydrolysis.

96% yield, white solid, mp = 92 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.46 (d, 1 H, $J = 8.3$ Hz, H-5), 7.32 (bd, 2 H, Ar), 7.18 (d, 1 H, $J = 1.8$ Hz, H-2), 7.08–7.13 (m, 3 H, H-6 and Ar), 5.60 (bt, 1 H, NHCO), 4.38 (d of AB, 2 H, $J = 5$ Hz, ArCH_2NH), 3.52 (q, 1 H, $J = 7.1$ Hz, CHCH_3), 3.06 (s, 3 H, SO_2CH_3), 3.03 (m, 4 H, CH_2NCH_2), 2.80 (m, 4 H, CH_2NCH_2), 1.52 (d, 3 H, $J = 7.1$ Hz, CHCH_3), 1.29 (s, 9 H, $\text{C}(\text{CH}_3)_3$)

IR (KBr) 3293, 2960, 1651, 1506, 1456, 1333, 1155 cm^{-1}

MS (FAB) m/z 473 (MH^+)

5.1.6.18. *N*-(4-*tert*-Butylbenzyl)-2-[3-methyl-4-(methylsulfonylamino)phenyl]propionamide (70): To a solution of **56** (110 mg, 0.27 mmol) and tetramethyl tin (72 mg, 0.4 mmol) in toluene (3 mL) was added tetrakis(triphenylphosphine)palladium (31 mg, 0.027 mmol, 0.1 eq). The mixture was refluxed for 6 h under a dry N_2 atmosphere. The reaction mixture was cooled to ambient temperature, filtered through Celite and concentrated *in vacuo*. The residue was extracted with EtOAc several times. The combined organic layers were washed with saturated aqueous NaCl and dried over MgSO_4 . Concentration *in vacuo* and subsequent purification by column chromatography (using EtOAc-hexane = 1 : 1) gave **9q** in 47 % yield.

white solid, mp = 72–74 °C

$^1\text{H NMR}$ (CDCl_3) 7.41–7.10 (m, 7 H, Ar-H), 6.29 (bs, 1 H, NHSO_2), 5.67 (bs, 1 H, NHCO), 4.56–4.29 (m, 2 H, ArCH_2NH), 3.52 (q, 1 H, $J = 6.39$ Hz, CHCH_3), 3.01 (s, 3 H, SO_2CH_3), 2.30 (s, 3 H, ArCH_3), 1.52 (d, 3 H, $J = 7.14$ Hz, CHCH_3), 1.30 (s, 9 H, $\text{C}(\text{CH}_3)_3$)

IR(KBr) 3285, 2953, 1650, 1501, 1488, 1321, 1156, 1024 cm^{-1}

MS (FAB) m/z 403 (MH^+)

5.1.6.19. *N*-(4-*tert*-Butylbenzyl)-2-[3-methoxy-4-(methylsulfonylamino)phenyl]propionamide (71): prepared from the carboxylic acid previously reported by the general coupling procedure.

83% yield, white solid, mp = 74–76 °C

$^1\text{H NMR}$ (CDCl_3) δ 7.1–7.5 (m, 5 H), 6.85–6.9 (m, 2 H), 6.75 (bs, 1 H, NHSO_2), 5.75 (bt, 1 H, NHCO), 4.39 (ddd of AB, 2 H, ArCH_2NH), 3.85 (s, 3 H, OCH_3), 3.54 (q, 1 H, $J = 7.1$

Hz, CHCH₃), 2.94 (s, 3 H, SO₂CH₃), 1.53 (d, 3 H, *J* = 7.1 Hz, CHCH₃), 1.31 (s, 9 H, C(CH₃)₃)

IR (KBr) 3286, 2961, 1652, 1548, 1338, 1271, 1156, 1026 cm⁻¹

MS (FAB) *m/z* 419 (MH⁺)

5.1.6.20. *N*-(4-*tert*-Butylbenzyl)-(2*S*)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (54*S*): prepared from the chiral (*S*)-carboxylic acid previously reported by the general coupling procedure.

98% yield, [α] = -15.5 (c 0.5, CHCl₃)

The spectra are identical to those of racemate **54**.

5.1.6.21. *N*-(4-*tert*-Butylbenzyl)-(2*R*)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (54*R*): The compound was prepared by following the procedure described for the synthesis of **1–51**.

96% yield, [α] = +18.4 (c 0.5, CHCl₃)

The spectra are identical to those of racemate **54**.

5.2. Molecular Modeling

Based on our rat TRPV1 tetramer homology model ^{**[ref#1]}, the human TRPV1 (hTRPV1) model was constructed as a tetramer. In the binding site, five residues are different between rat and human, and they were mutated as Ile514Met, Val518Leu, Val525Ala, Ser526Thr, and Met547Leu. Then, the side chains and backbone within 6 Å of the mutated residues were energy minimized using the Protein Composition Tool in SYBYL 8.1.1 (Tripos Int., St. Louis, MO, USA). The ligand structure was generated with Concord and energy minimized using the MMFF94s force field and MMFF94 charge until the rms of the Powell gradient was 0.05 kcal mol⁻¹Å⁻¹ in SYBYL. The flexible docking study on the hTRPV1 model was performed using GOLD v.5.0.1 (Cambridge Crystallographic Data Centre, Cambridge, UK). It uses a genetic algorithm (GA) and allows for full ligand flexibility and partial protein flexibility. The binding site was defined as 8 Å around capsaicin which was extracted from the docking result in the rTRPV1 model and merged into the aligned hTRPV1 model. The side chains of the important six residues for ligand binding (i.e., Tyr511, Ser512, Leu515, Leu547, Thr550, and Asn551) were set to be flexible with 'crystal mode'. The default parameters were used with the GoldScore scoring function, and 30 docking runs per ligand were performed. All computation calculations were undertaken on an Intel® Xeon™ Quad-core 2.5 GHz workstation with Linux Cent OS release 5.5.

Acknowledgments

This research was supported by Grants R11-2007-107-02001-0 from the National Research Foundation of Korea (NRF), the National Core Research Center (NCRC) program (No. 2011-0006244) of MEST and NRF through the Center for Cell Signaling & Drug Discovery Research at Ewha Womans University, and the intramural program of the National Institutes of Health, Center for Cancer Research, National Cancer Institute (project Z1A BC 005270).

References and Notes

1. Szallasi A, Blumberg PM. *Pharmacol. Rev.* 1999; 51:159–211. [PubMed: 10353985]
2. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D. *Neuron.* 1998; 21:531–543. [PubMed: 9768840]

3. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. *Nature*. 1997; 389:816–824. [PubMed: 9349813]
4. Zygmunt PM, Petersson J, Andersson DA, Chuang H-H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED. *Nature*. 1999; 400:452–457. [PubMed: 10440374]
5. Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, Cho S, Min KH, Suh YG, Kim D, Oh U. *Proc. Natl. Acad. Sci. USA*. 2000; 97:6155–6160. [PubMed: 10823958]
6. Walpole, CSJ.; Wrigglesworth, R. *Capsaicin in the Study of Pain*. San Diego, CA: Academic Press; 1993. p. 63
7. Appendino G, Szallasi A. *Life Sci*. 1997; 60:681–696. [PubMed: 9064473]
8. Szallasi A, Cruz F, Geppetti P. *Trends in Mol. Med*. 2006; 12:545–554. [PubMed: 16996800]
9. Voight EA, Kort ME. *Exp. Opin. Ther. Pat*. 2010; 20:1–16.
10. Lazar J, Gharat L, Khairathkar-Joshi N, Blumberg PM, Szallasi A. *Exp. Opin. Drug Discov*. 2009; 4:159–180.
11. Gunthorpe MJ, Chizh BA. *Drug Disc. Today*. 2009; 14:56–67.
12. Wong GY, Gavva NR. *Brain Res. Rev*. 2009; 60:267–277. [PubMed: 19150372]
13. Kym PR, Kort ME, Hutchins CW. *Biochem. Pharmacol*. 2009; 78:211–216. [PubMed: 19481638]
14. Wang Y, Szabo T, Welter JD, Toth A, Tran R, Lee J, Kang SU, Lee Y-S, Min KH, Suh Y-G, Park M-K, Park H-G, Park Y-H, Kim H-D, Oh U, Blumberg PM, Lee J. *Mol. Pharm*. 2002; 62:947–956. [published erratum appears in *Mol. Pharmacol*. 2003, 63, 958].
15. Wang Y, Toth A, Tran R, Szabo T, Welter JD, Blumberg PM, Lee J, Kang S-U, Lim J-O, Lee J. *Mol. Pharm*. 2003; 64:325–333.
16. Lee J, Lee J, Kang M, Shin M-Y, Kim J-M, Kang S-U, Lim J-O, Choi H-K, Suh Y-G, Park H-G, Oh U, Kim H-D, Park Y-H, Ha H-J, Kim Y-H, Toth A, Wang Y, Tran R, Pearce LV, Lundberg DJ, Blumberg PM. *J. Med. Chem*. 2003; 46:3116–3126. [PubMed: 12825950]
17. Suh Y-G, Lee Y-S, Min K-H, Park O-H, Kim J-K, Seung H-S, Seo S-Y, Lee B-Y, Nam YH, Lee K-O, Kim H-D, Park H-G, Lee J, Oh U, Lim J-O, Kang S-U, Kil M-J, Koo J-Y, Shin SS, Joo Y-H, Kim JK, Jeong Y-S, Kim S-Y, Park Y-H. *J. Med. Chem*. 2005; 48:5823–5836. [PubMed: 16134949]
18. Ryu H, Jin M-K, Kang S-U, Kim SY, Kang DW, Lee J, Pearce LV, Pavlyukovets VA, Morgan MA, Tran R, Toth A, Lundberg DJ, Blumberg PM. *J. Med. Chem*. 2008; 51:57–67. [PubMed: 18072720]
19. Stahly GP, Stahly BC, Lilje KC. *J. Org. Chem*. 1984; 49:579–580.
20. Lee JH, Lee Y, Ryu H, Kang DW, Lee J, Lazar J, Pearce LV, Pavlyukovets VA, Blumberg PM, Choi S. *J. Comput. Aided Mol. Des*. 2011




Figure 1.





Figure 2. Predicted binding mode of 54S in hTRPV1 homology model with surface representations


(A) Docked mode of **54S**. The key interacting residues are marked and displayed as a capped-stick representation with carbon atoms in white. The helices are colored in gray and the helices of the neighboring monomer are displayed in a line ribbon representation. The ligand is depicted as a ball-and-stick with carbon atoms in magenta and its van der Waals surface is presented with lipophilic potential property (LP) which ranges from brown (highest lipophilic area) to blue (highest hydrophilic area). Hydrogen bonds are drawn in black dashed lines, and non-polar hydrogens are undisplayed for clarity. (B) Surface representations of the docked **54S** and hTRPV1. The Fast Connolly surface of hTRPV1 was generated by MOLCAD and colored by the lipophilic potential. For clarity, the surface of hTRPV1 is Z-clipped and that of the ligand is in its carbon color. (C) Van der Waals surface of **54S** colored by the lipophilic potential.


**Figure 3.**


Reagents and Conditions: (a) *t*-BuOK, ethyl 2-chloropropionate, DMF; (b) Method A: H₂, Pd-C, MeOH, Method B: Fe, AcOH; (c) MsCl, pyridine; (d) LiOH, H₂O-THF; (e) 4-*t*-butylbenzylamine, EDC, CH₂Cl₂; (f) CF₃CO₂H, CH₂Cl₂(2:1); (g) TMS-diazomethane, MeOH; (h) BnNH₂, EDC, CH₂Cl₂; (i) CF₃CO₂H, CH₂Cl₂(1:2); (j) Sn(CH₃)₄, (PPh₃)₄Pd, toluene

Table 1

rTRPV1 activities of *N*-(4-*tert*-butylbenzyl)-2-[4-(methylsulfonylamino)phenyl] propionamide ligands



	R ₃	R ₂	R ₅	K _i (nM) Binding Affinity ^c	EC ₅₀ (nM) Agonism ^c	K _i (nM) Antagonism ^c
1				63.0	NE	54
2				53.5	NE	9.2
3				51.0	(17%) ^a	(84%) ^b
4				470 (±130)	NE	118 (±35)
53	H	H	H	106 (±34)	NE	17.5 (±1.6)
54	F	H	H	46.2 (±3.0)	NE	7.6 (±1.6)
55	Cl	H	H	30.7 (±7.4)	NE	29.5 (±8.5)
56	Br	H	H	7.4 (±1.5)	NE	25.0 (±7.4)
57	I	H	H	23.3 (±7.1)	NE	30.0 (±2.2)
58	F	H	F	19.9 (±6.1)	NE	7.4 (±2.1)
59	H	F	H	360 (±110)	NE	120 (±27)
60	H	Cl	H	1420 (±280)	NE	4500 (±1000)
61	CN	H	H	344 (±99)	NE	467 (±60)
62	CO ₂ Bu	H	H	6700 (±1200)	NE	(16%) ^b
63	CO ₂ H	H	H	NE	NE	NE
64	CO ₂ CH ₃	H	H	1606 (±53)	NE	952 (±120)
65	CONHBn	H	H	3710 (±470)	NE	(23%) ^b
66		H	H	WE	NE	(37%) ^b



	R ₃	R ₂	R ₅	Binding Affinity ^c		EC ₅₀ (nM)	K _i (nM)	K _i (nM)	
				WE	NE			Agonism ^c	Antagonism ^c
67		H	H	WE	NE	NE	NE	(34%) ^b	
68		H	H	7000 (±1600)	NE	NE	NE	(13%) ^b	
69		H	H	NE	NE	NE	NE	NE	
70	CH ₃	H	H	32.8 (±6.1)	NE	NE	NE	18.9 (±8.3)	
71	OCH ₃	H	H	540 (±130)	NE	NE	NE	232 (±71)	


^a only fractional calcium uptake compared with that induced by 300 nM capsaicin

^b only fractional antagonist

^c Values represent mean ± SEM from 3 or more experiments

NE, no effect. WE, weak effect (quantitation of fractional agonism/antagonism is from 1 – 3 experiments).

Table 2

TRPV1 activities of the two chiral isomers of **54**

rTRPV1			hTRPV1		
K _i (nM)	K _i (nM) [CAP] Antagonism	K _i (nM) Binding Affinity	K _i (nM) CAP Antagonism	K _i (nM) Antagonism	K _i (nM) (pH) Antagonism
54	46.2 (±3.0)	7.6 (±1.6)	89 (±17)	5.1 (±1.2)	12.7 (±3.6)
54R	750 (±200)	186 (±29)	2590 (±390)	217 (±57)	440 (±41)
54S	24.4 (±0.82)	4.16 (±0.67)	15.8 (±4.4)	0.49 (±0.13)	8.3 (±1.6)